{"id":"W2604105114","doi":"10.1200/jco.2012.30.15_suppl.tps8114","title":"A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Dexamethasone; Bortezomib; Antibody-dependent cell-mediated cytotoxicity; Internal medicine; Refractory (planetary science); Phases of clinical research; Progression-free survival; Oncology; Gastroenterology; Urology; Multiple myeloma; Chemotherapy; Antibody; Monoclonal antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002237879,0.001886511,0.003166691,0.0004855421,0.0005084223,0.001342797,0.001078643,0.001784076,0.007899119],"category_scores_gemma":[0.001565852,0.0009858988,0.001609958,0.000530212,0.001463297,0.001269026,0.0005772634,0.003618064,0.001720251],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009918857,"about_ca_system_score_gemma":0.001599234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001046837,"about_ca_topic_score_gemma":0.002679029,"domain_scores_codex":[0.999239,0.0003820937,0.00004068287,0.0001594433,0.00005014158,0.0001286106],"domain_scores_gemma":[0.9987326,0.0002485471,0.0002080594,0.0001013638,0.00006985468,0.0006394442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9692172,0.01591145,0.0006592757,0.0001837702,0.00037333,0.00004071776,0.0000520663,0.0002526923,0.004281593,0.00006084213,0.0004867841,0.008480321],"study_design_scores_gemma":[0.8528764,0.1439873,0.001414771,0.00001067624,0.0002577928,0.00003731374,0.00002268919,0.0002610931,0.0003589644,0.0000972544,0.0006640725,0.00001162084],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830039,0.001980633,0.0008874217,0.0007542041,0.0006420242,0.009173369,0.00130772,0.000140909,0.002109727],"genre_scores_gemma":[0.9761596,0.001846511,0.002922192,0.001903997,0.0005480938,0.01020982,0.001785977,0.00004966448,0.004574059],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007899119,"threshold_uncertainty_score":0.02642512,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1060364377978492,"score_gpt":0.4578265074100374,"score_spread":0.3517900696121882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}